The Soybean Peptide Vglycin Preserves the Diabetic β-cells through Improvement of Proliferation and Inhibition of Apoptosis
The Soybean Peptide Vglycin Preserves the Diabetic β-cells through Improvement of Proliferation and Inhibition of Apoptosis
复制标题
大豆肽 Vglycin 通过改善增殖和抑制细胞凋亡来保护糖尿病 β 细胞
DOI：
10.1038/srep15599
复制
发表时间：
2015-10-29
影响因子：
4.6
通讯作者：
Chen, Zhengwang
中科院分区：
文献类型：
--
作者：
Jiang, Hua;Tong, Yuxing;Chen, Zhengwang
补充产生胰岛素的胰腺β细胞对糖尿病有益。β细胞的数量主要通过自我新生来维持，以补偿β细胞的衰竭、损失或去分化。本文报道了一种从豌豆种子中分离纯化的多肽vglycin。在我们的糖尿病模型中，Vglycin通过促进β细胞的增殖、抑制其凋亡和去分化而表现出积极的作用。Vglycin促进了年轻的链脲佐菌素（STZ）诱导的1型糖尿病SD大鼠和老年的高脂饮食加（或不加）STZ诱导的2型糖尿病C57 BL/6小鼠中β细胞的恢复。我们证明了vglycin通过激活胰岛素受体和相应的转录因子来触发这种正信号传导。老年T2 DM小鼠中受损的胰岛素敏感性和葡萄糖耐量在长期vglycin治疗后显著改善，与炎症因子IL-1 β/6水平的改变一致。此外，在vglycin治疗后的小鼠模型中，能量消耗和体重显著降低。这些结果提供了对vglycin在长期糖脂毒性中改善β细胞功能的保护作用的了解。因此，vglycin可能代表通过补充内源性胰岛素阳性细胞来预防和治疗糖尿病的新治疗剂。
Replenishment of insulin-producing pancreatic beta-cells would be beneficial in diabetes. The number of beta-cells is maintained primarily by self-neogenesis to compensate for beta-cell failure, loss or dedifferentiation. We present here a polypeptide vglycin, which was isolated and purified from germinating pea seeds. Vglycin exhibited positive effects in our diabetic models by promoting the proliferation and suppressing the apoptosis and dedifferentiation of beta-cells. Vglycin promoted the restoration of beta-cells in both young streptozotocin (STZ)-induced type 1 diabetic SD rats and in aged high-fat diet with (or without) STZ-induced type 2 diabetic C57BL/6 mice. We demonstrated that vglycin triggers this positive signaling by activating the insulin receptor and corresponding transcription factors. Impaired insulin sensitivity and glucose tolerance in aged T2DM mice were dramatically improved after long-term vglycin treatment, consistent with the altered level of inflammatory factor IL-1 beta/6. In addition, energy expenditure and body weights were significantly decreased in the mouse models after vglycin therapy. These results provide insight into the protective effects of vglycin on ameliorating beta-cell function in standing glucolipotoxicity. Thus, vglycin may represent a new therapeutic agent for preventing and treating diabetes by replenishing endogenous insulin-positive cells.